Minor histocompatibility antigens - Big in tumour therapy

Trends in Immunology

Volumn 25, Issue 2, 2004, Pages 56-60

  Spierings, Eric ^a   Wieles, Brigitte ^a   Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HA 1 PROTEIN; HA 2 PROTEIN; HA 3 PROTEIN; HA 8 PROTEIN; HB 1 PROTEIN; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN; PROTEIN BCL 2A1; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CELL LINEAGE; DNA POLYMORPHISM; GENE REARRANGEMENT; GRAFT REJECTION; HEMATOPOIETIC CELL; HLA MATCHING; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMORPHIC LOCUS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SKIN EXPANSION; T LYMPHOCYTE; UPREGULATION; VIRUS TRANSFORMATION; Y CHROMOSOME;

EID: 0842324616     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.12.002     Document Type: Article

References (50)

1. Snell G.D. Methods for the study of histocompatibility genes. J. Genet. 49:1948;87-103.
2. Counce C., et al. Strong and weak histocompatibility fine differences in mice and their role in the rejection of homografts of tumors and skin. Ann. Surg. 144:1956;198-204.
3. Graff R.J., Bailey D.W. The non-H-2 histocompatibility loci and their antigens. Transplant. Rev. 15:1973;26-49.
4. Schultz J.S., et al. Contributions of H-2 and non H-2 genetic barriers. Immunogenetics. 3:1976;85-96.
5. Bevan M.J. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. J. Exp. Med. 142:1975;1349-1364.
6. Gordon R.D., et al. In vitro cell-mediated immune responses to the male specific (H-Y) antigen in mice. J. Exp. Med. 142:1975;1108-1120.
7. Goulmy E., et al. Alloimmunity to human H-Y. Lancet. 2:1976;1206.
8. Goulmy E., et al. Y-antigen killing by T cells of women is restricted by HLA. Nature. 266:1977;544-545.
9. Wallny H.J., Rammensee H.G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature. 343:1990;275-278.
10. Loveland B., et al. Maternally transmitted histocompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein. Cell. 60:1990;971-980.
11. Rotzschke O., et al. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science. 249:1990;283-287.
12. den Haan J.M., et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 268:1995;1476-1480.
13. Scott D.M., et al. Identification of a mouse male-specific transplantation antigen, H-Y. Nature. 376:1995;695-698.
14. Anonymous (2002) Report on the state of the art in blood and marrow transplantation. International Bone Marrow Transplantation Registry/Autologous Blood and Marrow Transplant Registry Newsletter 9, 4-11.
15. Van Aelst L., D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 11:1997;2295-2322.
16. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171:2001;1-10.
17. Frame M.C., Brunton V.G. Advances in Rho-dependent actin regulation and oncogenic transformation. Curr. Opin. Genet. Dev. 12:2002;36-43.
18. Klein C.A., et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J. Exp. Med. 196:2002;359-368.
19. Zheng Y., et al. Direct involvement of the small GTP-binding protein Rho in lbc oncogene function. J. Biol. Chem. 270:1995;9031-9034.
20. Subramaniam K., Seydoux G. Dedifferentiation of primary spermatocytes into germ cell tumors in C. elegans lacking the pumilio-like protein PUF-8. Curr. Biol. 13:2003;134-139.
21. Wilke M., et al. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies. Hematol. J. 4:2003;315-320.
22. Akatsuka Y., et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J. Exp. Med. 197:2003;1489-1500.
23. Dolstra H., et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J. Exp. Med. 189:1999;301-308.
24. Murata M., et al. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J. Exp. Med. 197:2003;1279-1289.
25. Dolstra H., et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J. Immunol. 158:1997;560-565.
26. Goulmy E. Minor histocompatibility antigens in man and their role in transplantation. Transplant. Rev. 2:1988;29-53.
27. James E., et al. Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood. 102:2003;388-393.
28. Verdijk, R.M. et al. (2003) Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 10.1182/blood-2003-05-1625 ( www.bloodjournal.org/ ).
29. Calvo R., Drabkin H.A. Embryonic genes in cancer. Ann. Oncol. 11:2000;207-218.
30. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev. 157:1997;125-140.
31. Mutis T., Goulmy E. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin. Hematol. 39:2002;23-31.
32. Marijt W.A., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2742-2747.
33. Miyazaki M., et al. Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells. Clin. Immunol. 107:2003;198-201.
34. Pierce R.A., et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J. Immunol. 167:2001;3223-3230.
35. Mermall V., et al. Unconventional myosins in cell movement, membrane traffic, and signal transduction. Science. 279:1998;527-533.
36. Toksoz D., Williams D.A. Novel human oncogene lbc detected by transfection with distinct homology regions to signal transduction products. Oncogene. 9:1994;621-628.
37. Zhang B., et al. A conserved RNA-binding protein that regulates sexual fates in the C. elegans hermaphrodite germ line. Nature. 390:1997;477-484.
38. D'Sa-Eipper C., et al. Bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res. 56:1996;3879-3882.
39. den Haan J.M., et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 279:1998;1054-1057.
40. Mommaas B., et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J. Immunol. 169:2002;3131-3136.
41. Spierings E., et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood. 102:2003;621-629.
42. Brickner A.G., et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J. Exp. Med. 193:2001;195-206.
43. Meadows L., et al. The HLA-A*0201-restricted H-Y antigen contains a post-translationally modified cysteine that significantly affects T cell recognition. Immunity. 6:1997;273-281.
44. Wang W., et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 269:1995;1588-1590.
45. Warren E.H., et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J. Immunol. 164:2000;2807-2814.
46. Vogt M.H., et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood. 96:2000;3126-3132.
47. Pierce R.A., et al. Cutting edge: The HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J. Immunol. 163:1999;6360-6364.
48. Vogt M.H., et al. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood. 95:2000;1100-1105.
49. Vogt M.H., et al. The DBY gene codes for an HLA-DQ5 restricted human male specific minor histocompatibility antigen involved in GvHD. Blood. 99:2002;3027-3032.
50. + T-helper cells in H-Y-mismatched transplantation. Lancet. 362:2003;610-615.